A review of current and prospective therapeutic approaches in the treatment of chronic obstructive pulmonary disease
DOI:
https://doi.org/10.69139/y43x0t54Keywords:
biomarkers, chronic obstructive pulmonary disease, inflammation, monoclonal antibodies, phosphodiesterase inhibitors, precision medicineAbstract
Background: Chronic obstructive pulmonary disease (COPD) is a progressive, heterogeneous disease representing a major socioeconomic burden and the fourth leading cause of death worldwide. Its complex pathogenesis, characterized by chronic inflammation and irreversible airway obstruction, justifies the current use of bronchodilators and anti- inflammatory drugs, although these treatments are often insufficiently effective.
Material and methods: Monoclonal antibodies such as dupilumab and mepolizumab have shown promising clinical efficacy. Dupilumab was recently approved by the U.S. Food and Drug Administration (FDA) for patients with uncontrolled COPD and eosinophilic inflammation. The dual PDE3/4 inhibitor ensifentrine, also FDA- approved, exhibits both bronchodilatory and anti- inflammatory properties. Another potential agent from this group is tanimilast. Additionally, ongoing research explores other compounds targeting various aspects of COPD pathogenesis.
Conclusion: Due to the disease’s complex nature, unmet therapeutic needs remain. Continued investigation into biological markers and innovative treatments may enable more effective, personalized management of COPD, improving clinical outcomes and quality of life.
Downloads
References
The Lancet Respiratory Medicine. (2023). Changing how we see COPD. The Lancet Respiratory Medicine, 11(12), 1035. https://doi.org/10.1016/S2213-2600(23)00433-2
World Health Organisation. (2024, November 6). Chronic obstructive pulmonary disease (COPD). https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
Boers, E., Barrett, M., Su, J. G., Benjafield, A. V., Sinha, S., Kaye, L., Zar, H. J., Vuong, V., Tellez, D., Gondalia, R., Rice, M. B., Nunez, C. M., Wedzicha, J. A., & Malhotra, A. (2023). Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. JAMA network open, 6(12), e2346598. https://doi.org/10.1001/jamanetworkopen.2023.46598
Global Initiative for Chronic Obstructive Lung Disease. (2025). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: 2025 report. https://goldcopd.org/2025-gold-report/
López-Campos, J. L., Tan, W., & Soriano, J. B. (2016). Global burden of COPD. Respirology (Carlton, Vic.), 21(1), 14–23. https://doi.org/10.1111/resp.12660
Miravitlles, M., & Ribera, A. (2017). Understanding the impact of symptoms on the burden of COPD. Respiratory research, 18(1), 67. https://doi.org/10.1186/s12931-017-0548-3
Corlateanu, A., Covantev, S., Mathioudakis, A. G., Botnaru, V., & Siafakas, N. (2016). Prevalence and burden of comorbidities in Chronic Obstructive Pulmonary Disease. Respiratory investigation, 54(6), 387–396. https://doi.org/10.1016/j.resinv.2016.07.001
Safiri, S., Carson-Chahhoud, K., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Ahmadian Heris, J., Ansarin, K., Mansournia, M. A., Collins, G. S., Kolahi, A. A., & Kaufman, J. S. (2022). Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. BMJ (Clinical research ed.), 378, e069679. https://doi.org/10.1136/bmj-2021-069679
Iheanacho, I., Zhang, S., King, D., Rizzo, M., & Ismaila, A. S. (2020). Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review. International journal of chronic obstructive pulmonary disease, 15, 439–460. https://doi.org/10.2147/COPD.S234942
Christenson, S. A., Smith, B. M., Bafadhel, M., & Putcha, N. (2022). Chronic obstructive pulmonary disease. Lancet (London, England), 399(10342), 2227–2242. https://doi.org/10.1016/S0140-6736(22)00470-6
Li, C. L., & Liu, S. F. (2024). Exploring Molecular Mechanisms and Biomarkers in COPD: An Overview of Current Advancements and Perspectives. International journal of molecular sciences, 25(13), 7347. https://doi.org/10.3390/ijms25137347
Brusselle, G. G., Joos, G. F., & Bracke, K. R. (2011). New insights into the immunology of chronic obstructive pulmonary disease. Lancet (London, England), 378(9795), 1015–1026. https://doi.org/10.1016/S0140-6736(11)60988-4
Brandsma, C. A., Van den Berge, M., Hackett, T. L., Brusselle, G., & Timens, W. (2020). Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine. The Journal of pathology, 250(5), 624–635. https://doi.org/10.1002/path.5364
Gopallawa, I., Dehinwal, R., Bhatia, V., Gujar, V., & Chirmule, N. (2023). A four-part guide to lung immunology: Invasion, inflammation, immunity, and intervention. Frontiers in immunology, 14, 1119564. https://doi.org/10.3389/fimmu.2023.1119564
Shan, M., Cheng, H. F., Song, L. Z., Roberts, L., Green, L., Hacken-Bitar, J., Huh, J., Bakaeen, F., Coxson, H. O., Storness-Bliss, C., Ramchandani, M., Lee, S. H., Corry, D. B., & Kheradmand, F. (2009). Lung myeloid dendritic cells coordinately induce TH1 and TH17 responses in human emphysema. Science translational medicine, 1(4), 4ra10. https://doi.org/10.1126/scitranlsmed.3000154
George, L., & Brightling, C. E. (2016). Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Therapeutic advances in chronic disease, 7(1), 34–51. https://doi.org/10.1177/2040622315609251
McGregor, M. C., Krings, J. G., Nair, P., & Castro, M. (2019). Role of Biologics in Asthma. American journal of respiratory and critical care medicine, 199(4), 433–445. https://doi.org/10.1164/rccm.201810-1944CI
Salazar, L. M., & Herrera, A. M. (2011). Fibrotic response of tissue remodeling in COPD. Lung, 189(2), 101–109. https://doi.org/10.1007/s00408-011-9279-2
Nurwidya, F., Damayanti, T., & Yunus, F. (2016). The Role of Innate and Adaptive Immune Cells in the Immunopathogenesis of Chronic Obstructive Pulmonary Disease. Tuberculosis and respiratory diseases, 79(1), 5–13. https://doi.org/10.4046/trd.2016.79.1.5
Uemasu, K., Tanabe, N., Tanimura, K., Hasegawa, K., Mizutani, T., Hamakawa, Y., Sato, S., Ogawa, E., Thomas, M. J., Ikegami, M., Muro, S., Hirai, T., & Sato, A. (2020). Serine Protease Imbalance in the Small Airways and Development of Centrilobular Emphysema in Chronic Obstructive Pulmonary Disease. American journal of respiratory cell and molecular biology, 63(1), 67–78. https://doi.org/10.1165/rcmb.2019-0377OC
Barnes P. J. (2022). Oxidative Stress in Chronic Obstructive Pulmonary Disease. Antioxidants (Basel, Switzerland), 11(5), 965. https://doi.org/10.3390/antiox11050965
Downloads
Published
Data Availability Statement
No new data were created or analyzed in this study. Data sharing is not applicable to this article.
Issue
Section
License
Copyright (c) 2026 Aleksandra Kotapka (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
